Navigation Links
ViroPharma to Release 2008 Third Quarter Financial Results on October 29, 2008
Date:10/14/2008

- Conference Call to Discuss Results to Be Held at 9:00 A.M. -

EXTON, Pa., Oct. 14 /PRNewswire-FirstCall/ -- ViroPharma Incorporated's (Nasdaq: VPHM) third quarter financial results for 2008 are expected to be released on Wednesday, October 29, 2008 before the open of the U.S. financial markets.

The company will host a conference call and live audio webcast at 9:00 a.m. Eastern Time on the same day. During the conference call, ViroPharma management will discuss the third quarter financial results for 2008 and other business.

The press release and the live webcast of the conference call will be accessible via ViroPharma's corporate website at http://www.viropharma.com. An audio archive will be available at the same address until November 15, 2008. To participate in the conference call, please dial 877-366-0713 (domestic) and 302-607-2000 (international). After placing the call, please tell the operator you wish to join the ViroPharma investor conference call.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/Products.aspx). ViroPharma currently focuses
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. ViroPharma to Present at Three October Healthcare Conferences
2. ViroPharma to Present at Three September Healthcare Conferences
3. ViroPharma To Acquire Lev Pharmaceuticals
4. ViroPharma Provides Update on Upcoming FDA Advisory Committee Meeting to Discuss Bioequivalence of Locally Acting Gastrointestinal Drugs
5. Viropharma Comments On Upcoming FDA Advisory Committee Meeting
6. ViroPharma to Present at Two Upcoming Healthcare Conferences
7. ViroPharma to Present at the Seventh Annual JMP Securities Research Conference
8. ViroPharma to Present at the Cowen & Company 28th Annual Healthcare Conference
9. ViroPharma to Present at the Susquehanna Financial Group Second Annual Significant Options in Healthcare Conference
10. ViroPharma to Release 2007 Fourth Quarter and Full Year Financial Results on February 27, 2008
11. ViroPharma to Present at the BIO CEO & Investor Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/4/2015)... , March 4, 2015 PDL BioPharma, Inc. (PDL) ... conversion rate for the: , 3.75% Convertible Senior ... shares of common stock per $1,000 principal amount or approximately ... conversion rate for the note is adjusted in connection with ... March 12, 2015, to all stockholders who own shares of PDL ...
(Date:3/4/2015)... March 4, 2015  Brooklyn residents now have a ... chronic pain and injuries. Nunzio Saulle , M.D., ... opening of his NJS Physical Medicine and Rehabilitation (PM&R) ... Thursday, March 5, 2015. Health Plus Management, LLC is ... located at 1178 Flatbush Avenue. This new PM&R practice ...
(Date:3/4/2015)... 04, 2015 Research and Markets ... the "Global Biologics and Biosimilars Industry Report ... The Global Biologics and Biosimilars Industry ... on the current state of the biologics and ... basic overview of the industry including definitions, classifications, ...
(Date:3/4/2015)... Proove Biosciences , a commercial ... to announce the launch of their CME-accredited course ... of Pain”. , The continuing medical education program ... year. The focus of the program is to ... treatments, integrate appropriate pain management techniques, and incorporate ...
Breaking Biology Technology:PDL BioPharma Announces Conversion Rate Adjustment for Convertible Note 2NJS Physical Medicine & Rehabilitation Opening on Flatbush Avenue, Brooklyn, NY 2Global Biologics and Biosimilars Industry Report 2015-2020 2Proove Biosciences Launches CME Accredited Program with Medscape 2Proove Biosciences Launches CME Accredited Program with Medscape 3
... NeoStem, Inc.,(NYSE Alternext US: NBS), which is pioneering the pre-disease ... medical need,today announced that it has completed an above market ... $1.25 per unit with each unit,consisting of one share of ... stock at $1.75 per share. , ...
... SAN FRANCISCO, Calif., Dec. 3 Portola,Pharmaceuticals, a ... in cardiovascular disease, inflammatory disease,and cancer, today announced ... novel,compounds that inhibit spleen tyrosine kinase (Syk) and ... presented at the annual meeting of the,American Society ...
... , , QUEBEC CITY, ... AEZS ; TSX: AEZ), a global biopharmaceutical company ... has completed the transaction under the previously announced purchase ... ("CHRP") relating to AEterna Zentaris, rights to royalties on ...
Cached Biology Technology:NeoStem Completes $500,000 Private Placement With Strategic Investor 2NeoStem Completes $500,000 Private Placement With Strategic Investor 3Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 2Portola Data on Its Novel Syk Inhibitors and Novel Universal Factor Xa Inhibitor Antidote to be Presented at 2008 American Society of Hematology (ASH) Meeting 3AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 2AEterna Zentaris Closes Sale of Cetrotide(R) Royalty Stream for $52.5 Million to Cowen Healthcare Royalty Partners 3
(Date:2/24/2015)... This report analyzes the worldwide markets for Face and ... and Voice Biometrics. The report provides separate comprehensive analytics for the ... Europe , Asia-Pacific , ... and Latin America . Annual estimates and forecasts ... historic analysis is provided for these markets. Market data and analytics ...
(Date:2/13/2015)... , Feb. 13, 2015 ACT ... company that aims to transform cancer genomic information ... that the company has raised US$ 8 million in ... Based in Taipei, Taiwan , ... ACTDrug™, ACTOnco™. With the aim to implement next ...
(Date:2/9/2015)... , Feb. 9, 2015  Lintec of America ... methods for carbon nanotube (CNT) macrostructures, including sheets, yarns ... Dallas (UTD). Leveraging the vast industrial resources ... Tokyo, Japan , Lintec of America is forming ... Richardson, TX , focusing on scaling up the ...
Breaking Biology News(10 mins):World Face and Voice Biometrics Industry 2World Face and Voice Biometrics Industry 3World Face and Voice Biometrics Industry 4World Face and Voice Biometrics Industry 5World Face and Voice Biometrics Industry 6World Face and Voice Biometrics Industry 7World Face and Voice Biometrics Industry 8World Face and Voice Biometrics Industry 9World Face and Voice Biometrics Industry 10World Face and Voice Biometrics Industry 11World Face and Voice Biometrics Industry 12World Face and Voice Biometrics Industry 13World Face and Voice Biometrics Industry 14World Face and Voice Biometrics Industry 15World Face and Voice Biometrics Industry 16ACT Genomics Raises $8 Million in its First Private Funding Round 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 2Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 3Lintec announces exclusive license to commercialize innovative carbon nanotube technology from the University of Texas at Dallas 4
... A family of biodegradable polymers called polyketals and their ... acute lung injury, acute liver failure and inflammatory bowel ... acid to disease locations in the body. "The ... get the drugs inside the body to the diseased ...
... PhD, Associate Professor of Neuroscience at LSU Health Sciences ... only naturally occurring fatty acids in the brain ... originally identified as the targets of THC (the psychoactive ... from neurodegenerative diseases like Alzheimer,s and Parkinson,s. Published in ...
... issue of the Journal of Lipid Research suggests ... the rising rate of diabetes, especially in children and young ... mechanism of inheritance; kids get half their genes from mom ... understand additional kinds of inheritance like metabolic programming, which occurs ...
Cached Biology News:Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 2Biodegradable polymers show promise for improving treatment of acute inflammatory diseases 3LSUHSC research reports new method to protect brain cells from diseases like Alzheimer's 2
...
GeneRacer is an advanced RACE (rapid amplification of cDNA ends) technique that improves the efficiency of amplifying full-length 5' and 3' cDNA ends. With the GeneRacer Kit you can:...
One-step, microplate or cuvet, colorimetric, linear detection range 0.6 mM to 100 mM. Procedure: 2 min....
assays for phosphatase, lipase, nucleoside triphosphatases (ATPase, GTPase etc). HTS and follow up studies for phosphatase inhibitors. Quantitation of phosphate content in protein, lipids, and DNA....
Biology Products: